Brain Diseases: Clinical Trials

409 trials for Brain Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

173 completed, 72 recruiting, 51 unknown, 39 terminated. 409 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1409Completed 173, Recruiting 72, Unknown 51, Terminated 39, Not yet recruiting 29, Withdrawn 22, Active not recruiting 17, Enrolling by invitation 5, Suspended 1

Follow Brain Diseases: new trials by email Literature Review of Brain Diseases trials Research Report on Brain Diseases

Trials (filtered) newest first · largest first

All 409 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
GS1168 injection - Phenylketonuria (PKU)
Early Phase 1Not yet recruitingGritgen Therapeutics Co., Ltd.92027-12-312026-09-10
Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke
Neuromuscular coordination enhancement (NICE) intervention, EMG Amplitude Biofeedback Exercise - Chronic Stroke-related Upper-extremity Motor Impairment, Motor Module-guided Rehabilitation Targeting Impaired Intermuscular Coordination and Motor Recovery
Early Phase 1Not yet recruitingUniversity of Houston482027-08-012026-06-18
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
Pegulicianine, Placebo - Carotid Artery Diseases, Peripheral Arterial Disease
Early Phase 1Not yet recruitingMassachusetts General Hospital252027-06-012026-11-10
hCG Treatment for Rehabilitation From a TBI
Ovidrel, Placebo - Traumatic Brain Injury
Early Phase 1Not yet recruitingVA Office of Research and Development502027-01-012026-10-19
Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia
Investigational Combination Product - Periventricular Leukomalacia, White Matter Disease
Early Phase 1WithdrawnMGAM LLC2027-01-012025-07-22
Cholinergic Enhancement of Theta
COBENFY KarXT (50/20 mg), Control - Epilepsy, Seizures
Early Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center502026-12-012026-09-29
Bayesian Optimization of DBS for Gait
Deep Brain Stimulation - Parkinson Disease (PD)
Early Phase 1RecruitingUniversity of Minnesota152026-12-012026-09-28
Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence
Botulinum Toxin Type A (BoNT-A) - Spasticity, Stroke
Early Phase 1Not yet recruitingInstituto Mexicano del Seguro Social2002026-12-012026-11-04
Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease
UX-DA003 - PARKINSON DISEASE (Disorder)
Early Phase 1RecruitingThe First Affiliated Hospital of Anhui Medical University122026-11-232026-11-03
Asciminib With or Without Sildenafil for Brain Tumors
Asciminib, Sildenafil, Surgical resection or biopsy - Brain Tumor
Early Phase 1Not yet recruitingWashington University School of Medicine122026-10-312026-09-11
Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring
EEG Record only - Epilepsy (Treatment Refractory)
Early Phase 1Not yet recruitingAdraxe Corp.152026-10-152026-09-16
Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation
Cobenfy KarXT pill (50/20 mg), Placebo - Epilepsy, Essential Tremor
Early Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center302026-10-012026-07-23
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental - Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Early Phase 1Not yet recruitingNoah Tech, Corp.6002026-09-012026-03-10
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
Norethindrone Acetate-Ethinyl Estradiol - Arginine Vasopressin Deficiency, Oxytocin Deficiency
Early Phase 1RecruitingMassachusetts General Hospital202026-08-172026-10-26
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
[11C]MODAG-005 - Parkinson Disease (PD), MSA - Multiple System Atrophy
Early Phase 1RecruitingMODAG GmbH92026-07-292026-07-31
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Panitumumab-IRDye800 - Meningioma, Glioblastoma
Early Phase 1RecruitingEben Rosenthal302026-07-072026-10-16
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
LY-N001 Injection - Parkinson's Disease (PD)
Early Phase 1Not yet recruitingLingyi Biotech Co., Ltd.182026-07-072026-07-06
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
Everolimus - Epilepsy, Drug Resistant
Early Phase 1RecruitingXuanwu Hospital, Beijing52026-07-012026-04-07
Expansion Study of ALT001 in Patients With Multiple System Atrophy
ALT001 - Multiple System Atrophy
Early Phase 1Recruitingyilong Wang602026-06-152026-09-09
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type
ALT001 - Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Early Phase 1Recruitingyilong Wang202026-06-102026-09-09

Showing 20 of 409. Sign in to see all of them.

Narrower conditions

Alzheimer Disease (63)  ·  Brain Neoplasms (62)  ·  Parkinson Disease (57)  ·  Stroke (55)  ·  Brain Injuries, Traumatic (24)  ·  Glioma (21)  ·  Cognitive Dysfunction (17)  ·  Glioblastoma (17)  ·  Epilepsy (16)  ·  Ischemic Stroke (14)  ·  Multiple System Atrophy (11)  ·  Cerebral Palsy (10)  ·  Brain Injuries (8)  ·  Dementia (8)  ·  Drug Resistant Epilepsy (8)

Broader conditions

Central Nervous System Diseases (408)  ·  Nervous System Diseases (407)  ·  Neurodegenerative Diseases (137)  ·  Vascular Diseases (98)  ·  Cardiovascular Diseases (97)  ·  Mental Disorders (96)  ·  Cerebrovascular Disorders (89)  ·  Neurocognitive Disorders (88)  ·  Pathological Conditions, Signs and Symptoms (85)  ·  Movement Disorders (83)  ·  Basal Ganglia Diseases (82)  ·  Neoplasms by Site (78)  ·  Neoplasms (77)  ·  Nervous System Neoplasms (77)

Interventions

Magnetic Resonance Spectroscopy (9)  ·  Sodium Chloride (5)  ·  Temozolomide (5)  ·  florbetapir (5)  ·  Bevacizumab (4)  ·  Botulinum Toxins, Type A (4)  ·  Deep Brain Stimulation (4)  ·  Propranolol (4)  ·  Saline Solution (4)  ·  2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (3)  ·  Atorvastatin (3)  ·  Biopsy (3)  ·  Dexamethasone (3)  ·  Donepezil (3)  ·  Fluorodeoxyglucose F18 (3)

Sponsors

University of Pennsylvania (7)  ·  University of Texas Southwestern Medical Center (7)  ·  Brigham and Women's Hospital (6)  ·  Massachusetts General Hospital (6)  ·  Mayo Clinic (6)  ·  Xuanwu Hospital, Beijing (6)  ·  Case Comprehensive Cancer Center (5)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (5)  ·  University of Florida (5)  ·  VA Office of Research and Development (5)  ·  Arizona State University (4)  ·  Avid Radiopharmaceuticals (4)  ·  Beijing Tiantan Hospital (4)  ·  CHDI Foundation, Inc. (4)  ·  Institute for Neurodegenerative Disorders (4)

Countries

United States (241)  ·  China (59)  ·  Canada (9)  ·  France (8)  ·  Netherlands (8)  ·  Denmark (7)  ·  United Kingdom (7)  ·  Sweden (6)  ·  Egypt (5)  ·  Germany (5)  ·  Spain (5)  ·  Belgium (4)  ·  Israel (4)  ·  Australia (3)  ·  Norway (3)

Top investigators

Danna Jennings, MD (4)  ·  Ela Plow, PhD (3)  ·  Liankun Ren, MD (3)  ·  Maryam Fouladi, MD (3)  ·  Bradley C Lega, MD (2)  ·  Carsten Kock-Jensen, MD (2)  ·  Cristina Sampaio, MD, PhD (2)  ·  David J Nutt, MD (2)  ·  David Sandberg, MD (2)  ·  Irene CM Cortese, M.D. (2)  ·  Jesse C. Dean, PhD (2)  ·  Johannes Jakobsen, MD, DMSc (2)

Results publications

PMID 10898704, PMID 11571371, PMID 12359244, PMID 18468545, PMID 19138338, PMID 19366446, PMID 20097391, PMID 20185616, PMID 20204561, PMID 20335583, PMID 20360543, PMID 20501908, PMID 21157444, PMID 21368663, PMID 21749363, PMID 22200394, PMID 22459048, PMID 22910531, PMID 22982823, PMID 23559265, PMID 23763450, PMID 23993913, PMID 25013996, PMID 25479121, PMID 25819304, PMID 26084406, PMID 26158265, PMID 26203461, PMID 26276377, PMID 26304864, PMID 26724101, PMID 26800377, PMID 27179600, PMID 27206648, PMID 27512927, PMID 27547509, PMID 27774033, PMID 27814297, PMID 27871449, PMID 28402865, PMID 28538134, PMID 28902040, PMID 28994123, PMID 29114823, PMID 29262425, PMID 29286983, PMID 29540584, PMID 29701252, PMID 29753889, PMID 29882765

NIH funding

K23AG030967 (2), P30CA138292 (2), R15HD114052 (2), 2018 (1), 2023 (1), 2025 (1), I01RX000825 (1), I01RX004545 (1), K23AG057794 (1), P01HL056693 (1), P20GM109040 (1), P30AG072958 (1), P30CA012197 (1), P30CA013330 (1), P30CA014089 (1)